A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Leiomyosarcoma; Uterine cancer
- Focus Therapeutic Use
- 02 Apr 2018 Planned primary completion date changed from 7 Jan 2018 to 7 Jan 2019.
- 05 Jun 2017 Status changed from suspended to recruiting.
- 25 Apr 2017 Results published in the Cancer